Skip to main content
. Author manuscript; available in PMC: 2019 May 11.
Published in final edited form as: Vaccine. 2018 Apr 12;36(20):2799–2808. doi: 10.1016/j.vaccine.2018.03.091

Figure 2.

Figure 2.

Antibody response to cPvCSP and cPvMSP1 proteins following priming immunization at day 0 with either the unmodified SAd36-cPvCSP/cPvMSP1 recombinant vector or the recombinant vector including the signal peptide sequence (SP-SAd36-cPvCSP/cPvMSP1) and two subsequent recombinant proteins boosts at days 20 and 40. A) Kinetics of antibody titers to cPvCSP. B) IgG1 and IgG2a antibody titers elicited against cPvCSP, 20 days after the final immunization. C) Antibody avidity against cPvCSP, determined by ammonium thiocyanate ELISAs 20 days after the final immunization. D) Kinetics of antibody titers to cPvMSP1. E) IgG1 and IgG2a antibody titers elicited against cPvMSP1, 20 days after the final immunization. F) Antibody avidity against cPvMSP1, determined by ammonium thiocyanate ELISAs 20 days after the final immunization. Statistical analysis was conducted using Mann Whitney test for antibody titers, and unpaired t-test for avidity to determine differences between the immunization regimens. Statistically significant differences are denoted by *(p < 0.05), **(p < 0.01), and *** (p<0.001).